Karyopharm Therapeutics Inc.KPTINASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 70% recommend buying.

Consensus Rating

Buy

20 analysts·High coverage

70%

Rating Distribution

Strong Buy

00%

Buy

1470%

Hold

420%

Sell

210%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 125% higher.

Bear Case

$6.00

-5%

Consensus

$14.17

+125%

Bull Case

$21.00

+233%

Price Range20 analysts

Low

Consensus

High

$6.00

$21.00

Current Target

Current Price

$6.31

Upside to Target

$7.86

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-5.92(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+66.95%

EPS—

FY2028

Rev+52.85%

EPS—

FY2029

Rev+8.16%

EPS+0.29%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+2.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 17, 2025Goldman Sachs

Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick

Target:$12.00

+89.6%from $6.33

Dec 17, 2025Piper Sandler

Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick

Target:$12.00

+89.6%from $6.33

Nov 4, 2025RBC Capital

Karyopharm price target lowered to $19 from $30 at RBC Capital

Target:$19.00

+239.3%from $5.60

Oct 13, 2025H.C. Wainwright

Karyopharm upgraded to Buy from Neutral at H.C. Wainwright

Target:$15.00

+172.7%from $5.50

Oct 9, 2025Robert W. Baird

Karyopharm price target lowered to $21 from $25 at Baird

Target:$21.00

+255.9%from $5.90

Oct 8, 2025Leerink Partners

Karyopharm price target lowered to $6 from $8 at Leerink

Target:$6.00

+1.5%from $5.91

Jun 10, 2024RBC Capital

RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI)

Target:$3.00

+215.4%from $0.95

Jan 10, 2023Leerink Partners

SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Lowers Price Target to $5

Target:$5.00

+76.1%from $2.84

Aug 23, 2022Robert W. Baird

Karyopharm (KPTI) Stock: $14 Target And Outperform Rating

Target:$14.00

+151.8%from $5.56

Mar 10, 2022RBC Capital

Karyopharm Therapeutics (KPTI) Stock: $8 Price Target And Sector Perform Rating

Target:$8.00

+23.3%from $6.49

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance